RTSL (Rapid Therapeutic Science Laboratories) YoY EBITDA Growth: -81.00% (As of Jun. 2023)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Rapid Therapeutic Science Laboratories YoY EBITDA Growth?

Rapid Therapeutic Science Laboratories RTSL +300.00% YoY EBITDA Growth is -81.00% as of Jun. 2023.

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months. Rapid Therapeutic Science Laboratories's YoY EBITDA Growth for the quarter that ended in Jun. 2023 was -81.00%.

Rapid Therapeutic Science Laboratories's EBITDA per Share for the three months ended in Jun. 2023 was $0.02.

Rapid Therapeutic Science Laboratories YoY EBITDA Growth Related Terms

Rapid Therapeutic Science Laboratories YoY EBITDA Growth Historical Data

* Premium members only.

The historical data trend for Rapid Therapeutic Science Laboratories's YoY EBITDA Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Rapid Therapeutic Science Laboratories YoY EBITDA Growth Chart

Rapid Therapeutic Science Laboratories Annual Data
Trend Mar13 Mar14 Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Dec21 Dec22
YoY EBITDA Growth
Get a 7-Day Free Trial Premium Member Only Premium Member Only -12,318.14 86.18 95.29 -20.00 108.08

Rapid Therapeutic Science Laboratories Quarterly Data
Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23
YoY EBITDA Growth Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 247.06 90.00 111.11 135.14 -81.00

Rapid Therapeutic Science Laboratories YoY EBITDA Growth Calculation

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months.

Rapid Therapeutic Science Laboratories's YoY EBITDA Growth for the fiscal year that ended in Dec. 2022 is calculated as:

YoY EBITDA Growth (A: Dec. 2022 )
=(EBITDA per Share (A: Dec. 2022 )-EBITDA per Share (A: Dec. 2021 ))/ | EBITDA per Share (A: Dec. 2021 ) |
=(0.016--0.198)/ | -0.198 |
=108.08 %

Rapid Therapeutic Science Laboratories's YoY EBITDA Growth for the quarter that ended in Jun. 2023 is calculated as:

YoY EBITDA Growth (Q: Jun. 2023 )
=(EBITDA per Share (Q: Jun. 2023 )-EBITDA per Share (Q: Jun. 2022 )) / | EBITDA per Share (Q: Jun. 2022 )) |
=(0.019-0.1)/ | 0.1 |
=-81.00 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about YoY EBITDA Growth →
What does a YoY EBITDA Growth of -81.00% mean?
Rapid Therapeutic Science Laboratories (RTSL) has a YoY EBITDA Growth of -81.00% as of Jun. 2023. YoY EBITDA Growth is the percentage change of EBITDA per share over the past 12-month. View historical data for Rapid Therapeutic Science Laboratories and its competitors.
Is Rapid Therapeutic Science Laboratories' YoY EBITDA Growth too high?
Rapid Therapeutic Science Laboratories' current YoY EBITDA Growth is -81.00%.
How does Rapid Therapeutic Science Laboratories' YoY EBITDA Growth compare to VRAYQ and NNMX?
Rapid Therapeutic Science Laboratories' YoY EBITDA Growth of -81.00% can be compared against companies in the Diversified Financial Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good YoY EBITDA Growth for a Diversified Financial Services company?
A good YoY EBITDA Growth depends on the Diversified Financial Services industry context. However, YoY EBITDA Growth should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high YoY EBITDA Growth mean?
A high YoY EBITDA Growth can signal that a stock is expensive relative to its fundamentals. YoY EBITDA Growth is the percentage change of EBITDA per share over the past 12-month. View historical data for Rapid Therapeutic Science Laboratories and its competitors. Rapid Therapeutic Science Laboratories's current YoY EBITDA Growth is -81.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Rapid Therapeutic Science Laboratories stock overvalued right now?
Rapid Therapeutic Science Laboratories (RTSL) has a current YoY EBITDA Growth of -81.00%. The current YoY EBITDA Growth is -81.00%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is YoY EBITDA Growth calculated?
YoY EBITDA Growth is calculated from a company's financial statements. For Rapid Therapeutic Science Laboratories (RTSL), the current YoY EBITDA Growth is -81.00% as of Jun. 2023. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Rapid Therapeutic Science Laboratories Business Description

Address 558 County Road 472, De Leon, TX, USA, 76444
Rapid Therapeutic Science Laboratories Inc currently has no operations and operates as a blank check company.